Zogenix International Limited
- Address
- The Pearce Building, West Street
Sponsor Overview
Specializations
Rare Epileptic Encephalopathies
Zogenix International Limited focuses on clinical research in CDKL5 deficiency disorder, Dravet syndrome, and Lennox-Gastaut syndrome, with an emphasis on seizure-related conditions affecting both children and adults.
- CDKL5 deficiency disorder
- Dravet syndrome
- Lennox-Gastaut syndrome
The sponsor’s trial portfolio reflects interest in severe epilepsy and developmental epileptic encephalopathies that require ongoing therapeutic management.
Seizure Control and Symptom Management
Research activity is centered on treatment approaches for reducing seizure burden and improving control in patients with difficult-to-treat seizure disorders.
- Adjunctive therapy
- Seizure reduction
- Epileptic encephalopathy
The sponsor’s clinical interests include therapies intended to support patients with persistent convulsive symptoms across different age groups.
Pediatric and Adult Neurology
The funded studies include both pediatric and adult populations, indicating a therapeutic focus that spans the lifespan in rare neurological disease.
- Pediatric neurology
- Adult epilepsy care
- Rare neurological disorders
This area of interest includes long-term management needs in patients living with chronic seizure syndromes.
Long-term Safety and Tolerability
Clinical research also examines the safety and tolerability of fenfluramine-based treatment in rare seizure conditions, with attention to extended use in routine care settings.
- Long-term safety
- Tolerability
- Fenfluramine
These studies align with therapeutic needs in chronic antiepileptic management for patients with refractory seizures.
Sponsored Trials
| Trial Name | Country | Status |
|---|---|---|
| Efficacy and Safety of Fenfluramine Hydrochloride in Pediatric and Adult Patients with CDKL5 Deficiency Disorder: A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study |  Austria Belgium Germany Ireland Italy Portugal Spain The Netherlands | Not Recruiting |
| Long-Term Safety Assessment of Fenfluramine Hydrochloride as Adjunctive Therapy in Patients with Dravet or Lennox-Gastaut Syndrome | Italy Poland Spain The Netherlands | Not Recruiting |
Data & Insights
This sponsor works with 1 molecule, of which 0 are not being studied by other sponsors.
This sponsor has worked with 24 sites across their trial portfolio.
Therapeutic Focus
- 1.Nervous System Diseases2 trials449 other sponsors
Partnered Research Centres
24 centres- Address
- Viale Gaetano Pieraccini 24, 50139 Florence
- Address
- Largo Del Pozzo 71, 41124 Modena
- Address
- Alameda Professor Hernani Monteiro, 4200-319 Porto
- Address
- Cooley Road, Crumlin, D12 PN40 Dublin
- Address
- Hippokrateslaan 10, Batiment 54, 1200 Woluwe-Saint-Lambert
- Address
- Wilton, T12 DC4A Cork
Want to get in touch with this sponsor?
Send a question and we'll pass it on to Zogenix International Limited.
Need a custom report on this sponsor?
Competitive positioning, market entry, partnership opportunities — tell us the question.
Is something out of date?
Tell us what needs correcting and we'll update this profile.